Previous Meetings

GBCC 2018

Global Breast Cancer Conference 2018

09:15-10:45
Symposium 1
Cutting-edge Technology to Support Decision Making in Breast Cancer Treatment
Venue: A
  • Liquid Biopsy: CTC, CTDNA, Exosome etc.
    Janice Tsang (Hong Kong Breast Oncology Group (HKBOG), Hong Kong)
  • Clinical Utility of Multigene Assays in Breast Cancer
    Woo-Chan Park (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
  • Artificial Intelligence in Treatment of Breast Cancer Patients: Need of the Day: Role of AI Watson for Oncology
    Somashekhar S. P. (Manipal Comprehensive Cancer Center, India)
Panel Discussion 1
How to Treat Good Responders to Neoadjuvant Chemotherapy
Venue: B
  • Can We Omit Surgery with Suggestion of pCR by Biopsy in the Breast?
    Keda Yu (Shanghai Cancer Center and Cancer Institute, Fudan Univ., China)
  • Evaluation of Axillary LNs after Neoadjuvant Systemic Therapy
    Min Jung Kim (Yonsei Univ. Severance Hospital, Korea)
  • Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy
    Eun Yoon Cho (Samsung Medical Center, Korea)
  • Radiation Therapy for Patients with pCR after Neoadjuvant Chemotherapy
    Won Park (Samsung Medical Center, Korea)
Education Session 1
New Techniques and Technology in Breast Screening
Venue: C
  • New Techniques and Technology in Breast Screening Including Contrast Enhanced Mammography
    Janice Sung (Memorial Sloan Kettering Cancer Center, U.S.A.)
  • Automated Breast US as Supplemental Screening Modality in Women with Dense Breasts
    Sung Hun Kim (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
  • Abbreviated Breast MRI for High-risk Breast Cancer Screening
    Woo Kyung Moon (Seoul National Univ. Hospital, Korea)
Oral Presentation 1
Venue: D
  • DEAD-BOX RNA HELICASE DP103 ENHANCES YAP SUMOYLATION FOR YAP-TEAD DEPENDENCE AND STATIN SENSITIVITY IN TRIPLE NEGATIVE BREAST CANCER
    Alan Prem Kumar (National Univ. of Singapore, Singapore)
  • RESVERATROL SUPPRESSES BREAST CANCER PROLIFERATION THROUGH INHIBITION OF STAT3 ACTIVATION AND M2-MACROPHAGE POLARIZATION
    Isabella Wai Yin Cheuk (The Univ. of Hong Kong, Hong Kong)
  • ESTROGEN RECEPTOR POSITIVE IS NOT ENOUGH TO PREDICT THE PROGNOSIS OF BREAST CANCER
    Jai Min Ryu (Samsung Medical Center, Korea)
  • CLINICOPATHOLOGICAL FACTORS AFFECTING DISTANT METASTASIS IN LOCOREGIONAL RECURRENCE OF BREAST CANCER
    Cheol Min Kang (ASAN Medical Center, Korea)
  • ULTRASOUND-GUIDED RESTAGING AND LOCALIZATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT CHEMOTHERAPY FOR GUIDANCE OF AXILLARY SURGERY IN BREAST CANCER PATIENTS: EXPERIENCE WITH ACTIVATED CHARCOAL
    Won Hwa Kim (Kyungpook National Univ. Hospital, Korea)
  • APPLICATION OF ROBOTIC SURGERY (DA VINCI) IN THE MANAGEMENT OF BREAST CANCER- PRELIMINARY RESULTS AND EXPERIENCE SHARING
    Hung-Wen Lai (Changhua Christian Hospital, Taiwan)
  • CHARACTERIZATION OF THE MICROBIOME OF BREAST TISSUE AND GUT IN KOREAN BREAST CANCER PATIENTS
    Nam Won Kim (Soonchunhyang Univ. Hospital Seoul, Korea)
  • PREDICTING THE RISK OF PERIPHERAL NEUROPATHY BY THE COMBINATION OF FOUR SERUM MICRORNAS
    Shoko Narita (National Cancer Center Hospital, Japan)
10:45-11:45
Plenary Lecture 1
Venue: A
  • Overview of Therapeutic Strategies for Early Breast Cancer Patients: Past, Present and Future
    Eric P. Winer (Dana-Farber Cancer Institute, U.S.A.)
12:00-12:45
Satellite Symposium 1
Venue: A
  • Ethnic Differences in the Treatment Landscape of Breast Cancer: Western vs. Asian
    Louis Chow (Organisation for Oncology and Translational Research, Hong Kong)
13:15-14:15
Plenary Lecture 2
Venue: A
  • Application of the Concept of Intrinsic Subtypes to Clinical Decision Making
    Charles M. Perou (Univ. of North Carolina at Chapel Hill, U.S.A.)
14:30-16:00
Symposium 2
Overcoming Resistance to HER2-directed Therapies
Venue: A
  • Heterogeneity of HER2: Mutation, Amplification, Expression and Clinical Implications
    So Yeon Park (Seoul National Univ. Bundang Hospital, Korea)
  • Biomarkers for HER2-directed Therapies: Past Failure and Future Perspectives
    Ian Krop (Dana-Farber Cancer Institute, U.S.A.)
  • Evolving Strategies to Overcome Resistance to HER2 Targeted Agents
    Sung-Bae Kim (ASAN Medical Center, Korea)
Panel Discussion 2
Issues with Mastectomy and Reconstruction
Venue: B
  • How to Make a Good Mastectomy for Reconstruction Based on the Anatomy
    Jin Zhang (Tianjin Medical Univ. Cancer Institute & Hospital, China)
  • Reconstruction with Autologous Tissue
    David Chang (Univ. of Chicago, U.S.A.)
  • Reconstruction with Implant
    Hak Chang (Seoul National Univ. Hospital, Korea)
Education Session 2
Healthy Living after Breast Cancer Treatment
Venue: C
  • Addressing Relationships Following a Breast Cancer Diagnosis: The Impact on Partners, Children and Caregivers
    Shoshana M Rosenberg (Dana-Farber Cancer Institute, U.S.A.)
  • The Effect of Exercise Recommendation on the Level of Physical Activity in Breast Cancer
    Justin Jeon (Yonsei Univ., Korea)
  • Heart Disease in Breast Cancer Survivors
    Jihyoun Lee (Soonchunhyang Univ. Hospital Seoul, Korea)
Invited Oral Presentation
Venue: D
  • No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-conserving Surgery
    Taein Yoon (Dongnam Inst. of Radiological & Medical Sciences, Korea)
  • Imaging Biomarker for Molecular Oncology: Focusing on HER2 Evaluation
    Ilhan Lim (Korea Cancer Center Hospital, Korea)
  • A Phase II Trial of Pan-HER Inhibitor Poziotinib, in Patients with HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior HER2 Therapies
    Yeon Hee Park (Samsung Medical Center, Korea)
  • Ribociclib Plus Goserelin and Tamoxifen or a Non-steroidal Aromatase Inhibitor (NSAI) for Premenopausal Women with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-negative (HER2–) Advanced Breast Cancer (ABC) in the Randomized Phase III MONALEESA-7 Trial
    Seock-Ah Im (Seoul National Univ. Hospital, Korea)
  • Different Prognosis of Young Breast Cancer Patients in Their 20s and 30s Depending on Subtype: A Nationwide Study from the Korean Breast Cancer Society
    Seok Won Kim (Samsung Medical Center, Korea)
16:00-17:45
Junior Doctors Forum
Venue: E
  • Know-how for How Asian Doctors Can Build a Career with a Global Perspective
    Soonmyung Paik (Yonsei Univ. College of Medicine, Korea)
  • Steps to Getting Your Manuscript Published in a High Quality Medical Journal
    Charles M. Balch (The Univ. of Texas MD Anderson Cancer Center, U.S.A.)
16:15-17:45
Symposium 3
Breakthrough in Triple Negative Breast Cancer
Venue: A
  • Current Approaches in Treatment of TNBC
    Soo Chin Lee (National Univ. Cancer Institute, Singapore)
  • PARP Inhibitors and DNA Repair
    Seock-Ah Im (Seoul National Univ. Hospital, Korea)
  • Novel Targets and Overview of Ongoing Clinical Trials
    Funda Meric-Bernstam (The Univ. of Texas MD Anderson Cancer Center, U.S.A.)
Panel Discussion 3
NGS in the Era of Personalized Therapy: A Valuable Compass or a Valueless Noise?
Venue: B
  • International Guidelines for the Use of NGS Panels
    Yang Wen-Tao (Fudan Univ., China)
  • Biomarker Driven Cancer Therapy by Multiple NGS Panels for Somatic Mutations
    Woong-Yang Park (Samsung Medical Center, Korea)
  • Application of Multiple NGS Panels for Germline Variation to Real Practice
    Ji Soo Park (Yonsei Cancer Center, Korea)
Education Session 3
State of the Art of the Lymphedema Treatment
Venue: C
  • Appropriate Concept of Prevention of Lymphedema at the Initial Treatment
    Zisun Kim (Soonchunhyang Univ. Hospital Bucheon, Korea)
  • Early-stage Lymphedema Detection and Conservative Treatment
    Eun Joo Yang (Seoul National Univ. Bundang Hospital, Korea)
  • Surgical Treatment Options for Advanced Lymphedema
    Jung-Ju Huang (Chang Gung Memorial Hospital, Taiwan)
Survivorship Session 1
Building up Evidences for Breast Cancer Survivorship Care in Precision Medicine Era
Venue: D
  • The Reality in the Follow-up of Breast Cancer Survivors
    Hyun Jo Youn (Jeonbuk National Univ. Hospital, Korea)
  • Comprehensive Analysis of National Health Insurance Data for Breast Cancer Survivorship
    Ho Hur (National Health Insurance Service Ilsan Hospital, Korea)
  • Benchmarking Breast Cancer Survival: International Collaborative Research Platform to Improve Patients Outcome
    Isabelle Soerjomataram (International Agency for Research on Cancer, France)
Back to Previous Meetings